Background Bone remodeling is a lifelong process due to the balanced activity of osteoclasts (OCs), the bone-reabsorbing cells, and osteoblasts (OBs), and the bone-forming cells. This equilibrium is regulated by numerous cytokines, but it has been largely demonstrated that the RANK/RANKL/osteoprotegerin and Wnt/β-catenin pathways play a key role in the control of osteoclastogenesis and osteoblastogenesis, respectively. The pro-osteoblastogenic activity of the Wnt/β-catenin can be inhibited by sclerostin and Dickkopf-1 (DKK-1). RANKL, sclerostin and DKKs-1 are often up-regulated in bone diseases, and they are the target of new monoclonal antibodies. Data sources The authors performed a systematic literature search in PubMed and EMBASE to June 2018, reviewed and selected articles, based on pre-determined selection criteria. Results We re-evaluated the role of RANKL, osteoprotegerin, sclerostin and DKK-1 in altered bone remodeling associated with some inherited and acquired pediatric diseases, such as type 1 diabetes mellitus (T1DM), alkaptonuria (AKU), hemophilia A, osteogenesis imperfecta (OI), 21-hydroxylase deficiency (21OH-D) and Prader-Willi syndrome (PWS). To do so, we considered recent clinical studies done on pediatric patients in which the roles of RANKL-RANK/osteoprotegerin and WNT-ß-catenin signaling pathways have been investigated, and for which innovative therapies for the treatment of osteopenia/osteoporosis are being developed. Conclusions The case studies taken into account for this review demonstrated that quite frequently both bone reabsorbing and bone deposition are impaired in pediatric diseases. Furthermore, for some of them, bone damage began in childhood but only manifested with age. The use of denosumab could represent a valid alternative therapeutic approach to improve bone health in children, although further studies need to be carried out.
Introduction
Bone remodeling and appropriate growth are controlled by genetic factors, hormones, nutritional status, vitamin D levels, and exercise. In particular, bone strength is mainly determined by the peak of bone mass achieved during childhood and adolescence [1] . Pediatric disorders can lead to an impaired peak of bone mass and accelerated bone loss, thus resulting in an increased risk for osteoporosis and fractures. Bone health depends on the correct balance between the activity of osteoclasts (OCs), the bone-reabsorbing cells, and osteoblasts (OBs), the bone-forming cells. Indeed, most of the bone diseases reflect the imbalance of OC and OB activity in the remodeling process. OCs derive from the fusion of marrow-derived mononuclear phagocytes, the OC precursors (OCPs), which circulate in peripheral blood [2] . OCPs differentiate under the influence of two cytokines, the macrophagecolony stimulating factor (M-CSF) and the receptor activator of nuclear factor-κB ligand (RANKL) [3] . RANKL is expressed on OBs and stromal cells as a membrane-bound protein, and cleaved into a soluble molecule (sRANKL) by metalloproteinase [3] . It promotes differentiation and fusion of OCPs and activates mature OCs to reabsorb bone by binding to its specific receptor RANK [3] . Osteoprotegerin (OPG) is a soluble decoy receptor secreted by OBs and bone marrow stromal cells which binds to RANK and prevents the osteoclastogenic effect of RANKL [3] (Fig. 1 ). RANKL and OPG are also secreted by activated T-cells which represent a key paracrine link between bone metabolism and the immune system [4] . Recently, WNT-ß-catenin signaling pathway, also called the canonical Wnt pathway, has been shown to have an important role in the control of osteoblastogenesis and bone formation [5] (Fig. 2) . Wnt-signaling increases bone mass through several mechanisms including renewal of stem cells [6] , stimulation of pre-osteoblast replication [7] , induction of osteoblastogenesis [7] , and inhibition of osteoblast and osteocyte apoptosis [8] . Sclerostin and Dickkopf-1 (DKK-1) secrete Wnt-signaling inhibitors which play a key role in regulating bone mass [9, 10] . DKK-1 blocks the maturation of OBs, decreases OPG levels and increases RANKL expression, thus shifting the OPG/RANKL ratio in favor of bone resorption. The role of RANKL/OPG and WNT-ß-catenin signaling pathways in bone diseases has been established by experimental and clinical studies [11] [12] [13] . The focus of this review is to provide an update on the role of RANKL, OPG, sclerostin and DKK-1 in the altered bone remodeling associated with some inherited and acquired pediatric diseases, such as type 1 diabetes mellitus (T1DM), alkaptonuria (AKU), hemophilia A, osteogenesis imperfecta (OI), 21-hydroxilase deficiency (21OH-D) and Prader-Willi syndrome (PWS). We selected those pediatric diseases in which the role of both RANKL-RANK/OPG and WNT-ß-catenin signaling pathways has been investigated (Table 1) , and for which innovative therapies, such as the use of monoclonal antibodies for the treatment of osteopenia/osteoporosis are being developed.
Type 1 diabetes mellitus
Type 1 diabetes mellitus (T1DM) is one of the most common chronic diseases of pediatric age. T1DM is associated with reduced bone mass and alterations of bone microarchitecture which start in childhood at the onset of diabetes [14, 15] . The adolescents with T1DM have decreased peak of bone mass, and increased risk for osteoporosis and fractures later in life [16, 17] . Several mechanisms have been proposed for the decrease in bone mineral density (BMD) in T1DM, including the lack of osteoanabolic pancreatic hormones, in particular insulin [18] , low levels of insulin-like growth factor 1 (IGF-1) [19] , chronic hyperglycemia [20] , and the accumulation of advanced glycation end products (AGEs) [21] .
An upregulation of the RANKL/OPG pathway, with elevated parathyroid hormone levels, has been found in 40 T1DM children, indicating an increased bone resorption and a predisposition to decreased bone mass [22] .
Furthermore, the involvement of Wnt-signaling inhibitors has been demonstrated in T1DM children. In particular, higher levels of sclerostin and DKK-1 have been observed in 106 children and adolescents with T1DM, both on treatment with multiple daily injections (MDI) and continuous subcutaneous infusion of insulin (CSII), compared to controls [23] . Importantly, this study demonstrated that the subjects treated with CSII had a better glycaemic control than those on MDI regimen, and showed lower levels of sclerostin and DKK-1 than subjects treated with MDI [23] . With adjustment for age, multiple linear regression analysis for DKK-1 and sclerostin as dependent variables showed that levels of HbA1c%, glucose, 25(OH)-vitamin D, osteocalcin, PTH, years of diabetes, AD-SoS-Z-score and BMI-SDS are the most important predictors [23] .
Increased levels of DKK-1 associated with low BMD were also found in 40 children and adolescents with T1DM, as expression of a Wnt/β catenin downregulation [24] . In a recent study, Faienza et al. [25] has demonstrated that in T1DM subjects on CSII treatment, the levels of DKK-1 negatively correlated with the circulating amounts of irisin, a myokine involved both in bone and glucose metabolism [26] [27] [28] . These findings suggested that irisin levels are closely related to a better metabolic control and an improved bone mass [25] . Fig. 2 The OPG/RANKL/RANK system: RANKL-RANK interaction leads to osteoclast differentiation. OPG is the decoy receptor for RANKL: RANKL-OPG interaction blocks RANKL-RANK binding Table 1 Receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), sclerostin and Sclerostin and Dickkopf-1 (DKK-1) modulation in some pediatric diseases
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High levels [56] [57] [58] Low levels [56, 57] High levels [58] Prader-Willi syndrome High levels [64] Low levels [64] High levels [64] Normal levels [64] In contrast, Tsentidis et al. [29] found similar levels of sclerostin in 40 diabetic children and controls, although, consistently with results by Faienza et al., sclerostin levels were higher in male than female patients, and correlated with bone-formation markers and pubertal stage. Neumann et al. [30] reported that both males and females with T1DM had higher serum levels of sclerostin compared with controls, but they did not find a correlation between serum sclerostin levels and markers of bone metabolism.
In conclusion, RANKL/OPG pathway, DKK-1 and sclerostin seem to be involved in the altered bone metabolism of T1DM children. Moreover, CSII treatment, through an enhanced glycaemic control, improves bone health by the regulation of the Wnt pathway inhibitors and irisin levels [23, 25] . Although recent data demonstrated that oral vitamin D supplementation increases insulin secretion in T1DM children [31] , further studies are needed to determine if vitamin D can boost bone health in these subjects.
Alkaptonuria
Alkaptonuria (AKU) is a rare inherited genetic disorder characterized by the deficiency of the enzyme homogentisate 1,2-dioxygenase involved in phenylalanine and tyrosine catabolism [32] , with consequent accumulation of the homogentisic acid [33] . Children with AKU may develop a severe ochronotic arthropathy at 40-50 years of age [34] , a condition due to the wide hyaline cartilage pigmentation [34] and increased OC activity [35] . Brunetti et al. [36] evaluated serum levels of RANKL, OPG, sclerostin and DKK-1 in a group of seven AKU adults and two children compared to controls. Higher levels of RANKL and C-terminal telopeptide of collagen type 1 (CTX-1), and lower OPG serum levels were observed in adult AKU subjects than controls, but not in AKU children, suggesting that the enhanced bone remodeling occurs with aging. However, a spontaneous osteoclastogenesis supported by RANKL, TNF-α and LIGHT was already evident in AKU children, despite the absence of injury [36] . TNF-α and LIGHT are two cytokines known to synergize with RANKL to induce osteoclastogenesis [37] [38] [39] . No differences were found between AKU patients and controls as regard sclerostin and DKK-1 [36] .
The studies mentioned demonstrated that bone damage begins in childhood and becomes evident with aging. Moreover, an enhanced OC activity with the involvement of RANKL/OPG pathway seems to play a key role in determining bone loss in AKU subjects, whereas osteoblastogenesis would not be impaired.
The development of a therapeutic approach that targets OC activity could prevent bone damage in AKU adult subjects.
Hemophilia A
Hemophilia A is an X-linked recessive bleeding disorder characterized by deficiency in factor VIII clotting activity. Children with hemophilia A have low BMD and a high risk for osteoporosis and fractures later in life. The pathogenesis of low BMD in haemophilics is multifactorial and includes immobilization as well as arthropathy. Christoforidis et al. [40] found higher RANKL serum levels and low OPG levels in a group of 26 haemophilic boys than controls. Previous studies in adult haemophilics did not found any significant difference in OPG and RANKL serum levels among patients and controls [41] .
A recent study evaluated the serum levels of the Wntsignaling inhibitors, sclerostin and DKK-1, as well as of RANKL and OPG in a group of 44 children (mean age 10.11 ± 6.1 years) with severe hemophilia A, compared to controls [42] . Sclerostin levels were higher in haemophilic subjects than controls, while no significant differences were found between patients and controls in OPG, RANKL and DKK-1 serum levels. Furthermore, it would seem to be a compensatory increase in the boneformation rate demonstrated by high osteocalcin levels in subjects with hemophilia A. In particular, among the haemophilics, those who had PTH beyond the physiological range showed significant higher RANKL levels and lower OPG/RANKL ratio than patients with normal PTH levels [42] .
The results arising from the above studies demonstrated that the WNT-ß-catenin signaling pathway inhibitor, sclerostin, could be accountable for bone loss in hemophilia A, which seems to be more evident in adulthood, as young haemophilics showed high levels of osteocalcin.
Further studies need to be carried out to assess whether sclerostin measurements should be introduced in routine clinical evaluation of low bone mass in children with hemophilia A.
Osteogenesis imperfecta
Osteogenesis imperfecta (OI) is a rare genetic disorder of the collagen synthesis that affects bone and connective tissue, caused by both inheritance and spontaneous genetic mutations. OI is characterized by low bone mass and reduced bone strength which are responsible for bone fragility, bone deformity and growth deficiency [43] .
High RANK, RANKL and OPG levels have been observed in Brtl mice, a knock-in model for moderately severe OI having a G349C substitution in half of type I collagen alpha-1 chains, although a normal RANKL/OPG ratio is maintained [44] . Moreover, TRAP + precursors were found to be markedly elevated in Brtl marrow cultures, suggesting an increase of bone-reabsorbing OCs, while osteoblast function was found to be reduced [44] .
Recently, higher serum levels of DKK-1 and RANKL have been demonstrated in 18 OI children treated and untreated with cyclic intravenous neridronate than the controls [45] . As regard to sclerostin and OPG, significant difference between patients and controls has been found [45] . Interestingly, the lymphomonocytes from OI children expressed high amounts of RANKL and low levels of OPG, thus supporting the high osteoclastogenic potential of peripheral blood mononuclear cells (PBMCs) from these patients. In fact, the neutralization of RANKL through RANK-Fc inhibited osteoclastogenesis [45] . The high osteoclastogenesis potential of PBMCs from OI children was sustained by the elevated percentage of circulating OC precursors and TNF-α, whose major source is represented by monocytes.
The effects of bisphosphonates have been observed both in experimental and clinical studies [46] [47] [48] [49] [50] [51] . The use of alendronate increased BMD and reduced fractures in these oim/oim mice, an animal model of moderate-to-severe OI [46] [47] [48] , whereas RANKL inhibition also increased BMD but had no effect on fracture incidence [49, 50] . Recently, Bargman et al. compared bisphosphonates therapy and RANKL inhibition in neonatal oim/oim and wild-type mice and observed the same efficacy in decreasing fracture incidence and improving bone properties [52] . Furthermore, successful results have been obtained treating patients with type VI OI with anti-RANKL antibody (denosumab) [53] .
The above studies demonstrated that besides the classical treatment of OI with bisphosphonates, the use of drugs neutralizing RANKL and DKK-1 could improve OB and OC activity in OI patients. 21 -Hydroxylase deficiency (21-OHD) is the most common cause of congenital adrenal hyperplasia (CAH), a group of autosomal recessive disorders involving impaired synthesis of cortisol from cholesterol by the adrenal cortex. Children with 21-OHD need chronic glucocorticoid (cGC) therapy to replace congenital deficit of cortisol synthesis, thus they are at risk of developing drug-induced osteoporosis [54, 55] . A high osteoclastogenic potential has been observed in patients with 21-OHD under cGC treatment [56] . This spontaneous osteoclastogenesis seems to correlate with the higher number of circulating osteoclast precursor observed in 21-OHD patients compared to controls, but also with the T-cell activity. In fact, T-cells from 21-OHD patients overexpressed RANKL mRNA and proteins and underexpressed OPG mRNA and proteins with respect to the controls [56] . Accordingly, the serum levels of RANKL and OPG resulted higher and lower in 21-OHD children, respectively, compared to the controls [56] . According with these data, the study of Abd El Dayem et al. [57] reported high serum levels of RANKL and low levels of OPG in 30 children with CAH treated with GCs, even if the BMD assessed by dual energy X-ray absorptiometry (DXA) was normal. Furthermore, Metwalley et al. [58] found higher serum levels of RANKL associated with lower BMD values for vertebrae and proximal femur in a group of 28 children with classical form of 21-OHD on treatment with GCs than the healthy controls.
21-Hydroxylase deficiency
High serum levels of DKK-1 have been found in the sera from 18 patients with (21-OHD) treated with GCs compared to controls [59] . These high DKK-1 serum levels were expressed by circulating T-lymphocytes, monocytes and neutrophils from 21-OHD patients.
From the analysis of the above studies, we can make three important observations. First, elevated serum levels of DKK-1 were found in 21-OHD patients on cGC treatment with respect to controls. Second, monocytes, T-lymphocytes, and neutrophils from 21-OHD patients on cGC treatment expressed high levels of DKK-1. Third, the serum from patients can directly inhibit OB differentiation in vitro as well as RANKL expression in OBs, and these effects were neutralized by the addition of an anti-DKK-1 antibody in the cultures.
In conclusion, it would seem that both RANKL/OPG axis and Wnt-signaling inhibitors are involved in the pathogenesis of bone loss associated with 21-OHD. Further studies are needed to evaluate if these bone cytokines could represent possible biomarkers of bone disease in these subjects.
Prader-Willi syndrome
The Prader-Willi syndrome (PWS) is a rare genetic disorder caused by absence of expression of the paternal alleles in 15q11.2-q13 region [60] . Neonatal hypotonia, progressive hyperphagia with severe obesity in early childhood, hypogonadism, delay of psychomotor development and behavioral problems are the main clinical signs. PWS patients have a typical bone phenotype with short stature, low BMD, reduced bone mineral content and scoliosis [61] . Moreover, a higher prevalence of osteoporosis and fractures has been reported [60] . These alterations could result from reduced production of gonadal hormones during puberty, and deficiency in GH secretion during childhood and adolescence [62, 63] . Brunetti et al. [64] evaluated RANKL, OPG and sclerostin levels in a group of 12 PWS children and 14 adults. RANKL serum levels were increased both in pediatric and adult patients, while OPG was significantly reduced. Sclerostin levels were increased in children and reduced in adult patients, while any significant difference regarding DKK-1 levels was found between PWS patients and controls. Multiple linear regression analysis showed that the most important predictors for RANKL, OPG, and sclerostin were BMD and osteocalcin in PWS children, and GH and sex steroid replacement treatment in PWS adults.
Thus, PWS children showed a high bone turnover, probably mediated by GH therapy, whereas PWS adults had a low bone turnover, both conditions that may be responsible for the altered BMD associated with this genetic disease.
In conclusion, the involvement of RANKL, OPG, and sclerostin has been demonstrated in the altered bone turnover of PWS patients. Thus, these molecules could be new potential pharmacological targets to improve bone health in these subjects, including the use of human antibodies against RANKL. Moreover, the low 25(OH)-vitamin D levels found in PWS children suggest that vitamin D supplementation could improve BMD in these subjects.
RANKL and sclerostin as potential new therapeutic targets
The reduction of BMD is associated with several diseases and the classical therapeutic approach includes bisphosphonates (BPs) as anti-resorbing agents [65] . BPs show a high affinity for bone hydroxyapatite, thus determining their long skeletal half-life, with consequent long duration of their effect. These properties imply that they are not frequently used in children [65] . The same restriction is also evident for the teriparatide which mimics the anabolic activity of PTH. Interestingly, the discovery of RANKL led to the production of denosumab, an antibody that neutralizes RANKL, thus working as an anti-resorptive agent. It improves BMD with low incidence of side effects [65] . The main property of denosumab is the reversibility of its effect: this is important to preserve skeletal growth in children. Thus, denosumab represents a possible treatment to counteract the bone disease, in both children and adolescents. Moreover, denosumab has been used in OI with encouraging results although further studies are needed [66] . More recently, romosozumab has been proposed, an anabolic agent that neutralizes sclerostin, thus favoring bone formation [65] . Despite its role on the improvement of BMD, the cardiovascular adverse effects linked to the use of romosozumab limits its use in clinical practice [65] .
Conclusions
The studies taken into account for this review demonstrated that quite frequently both bone reabsorbing and bone deposition are impaired in pediatric diseases.
Furthermore, for some of them, bone damage began in childhood but only manifested with age. The effects of BPs last for a long duration, so they are not frequently used in children. Instead, denosumab represents a valid alternative therapeutic approach to improve bone health in children, although further studies need to be carried out.
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